Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.

Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials

EWER K., (2023), Clinical and Experimental Immunology

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.

Mentzer AJ. et al, (2023), Nat Med, 29, 147 - 157

Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination.

Foster WS. et al, (2022), Cell Rep Med

Low-dose IL-2 reduces IL-21+ T cell numbers and induces anti-inflammatory gene expression in type 1 diabetes

Zhang J. et al, (2022), Nature Communications

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.

Li G. et al, (2022), Lancet, 399, 2212 - 2225

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Ogbe A. et al, (2022), JCI Insight, 7

Low-dose IL-2 reduces IL-21+ T cells and induces a long-lived anti-inflammatory gene expression signature inversely modulated in COVID-19 patients

Zhang J-Y. et al, (2022)

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.

COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk None. and COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium None., (2022), Cell, 185, 916 - 938.e58

Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

Ogbe A. et al, (2021)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

EWER K. et al, (2021), The Lancet